At the news
? MIXEDIMPACT 8/10 PRESS-RELEASE filed Mar 25, 2026 at 16:01 ET
Celcuity announced strong clinical results from the PIK3CA wild-type cohort of its Phase 3 VIKTORIA-1 trial, with gedatolisib showing a median PFS of 16.6 months versus 1.9 months for fulvestrant, alongside FDA acceptance of its NDA with Priority Review and a PDUFA date of July 17, 2026. However, the company reported a widening net loss of $177.0 million in 2025 compared to $111.8 million in 2024, driven by higher R&D and G&A expenses ahead of a potential 2026 launch.
- FDA accepted NDA for gedatolisib with Priority Review; PDUFA date set for July 17, 2026
- Phase 3 VIKTORIA-1 trial in PIK3CA WT HR+/HER2- ABC showed median PFS of 16.6 months vs 1.9 months (HR=0.14)
- Median time to definitive deterioration in well-being was 23.7 months vs 4.0 months (HR=0.39)
- Full-year 2025 net loss was $177.0 million ($3.79/share), up from $111.8 million ($2.83/share) in 2024
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access